184 related articles for article (PubMed ID: 37543185)
21. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.
Stevens WW; Peters AT; Hirsch AG; Nordberg CM; Schwartz BS; Mercer DG; Mahdavinia M; Grammer LC; Hulse KE; Kern RC; Avila P; Schleimer RP
J Allergy Clin Immunol Pract; 2017; 5(4):1061-1070.e3. PubMed ID: 28286156
[TBL] [Abstract][Full Text] [Related]
22. Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia.
Ho J; Bailey M; Zaunders J; Mrad N; Sacks R; Sewell W; Harvey RJ
Clin Exp Allergy; 2015 Feb; 45(2):394-403. PubMed ID: 25429730
[TBL] [Abstract][Full Text] [Related]
23. Aspirin-exacerbated respiratory disease.
Wangberg H; White AA
Curr Opin Immunol; 2020 Oct; 66():9-13. PubMed ID: 32299015
[TBL] [Abstract][Full Text] [Related]
24. Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease.
Jerschow E; Edin ML; Chi Y; Hurst B; Abuzeid WM; Akbar NA; Gibber M; Fried MP; Han W; Pelletier T; Ren Z; Keskin T; Roizen G; Lih FB; Gruzdev A; Bradbury JA; Schuster V; Spivack S; Rosenstreich D; Zeldin DC
J Allergy Clin Immunol Pract; 2019; 7(5):1580-1588. PubMed ID: 30580047
[TBL] [Abstract][Full Text] [Related]
25. Mast Cells in Aspirin-Exacerbated Respiratory Disease.
Abud EM; White AA
Curr Allergy Asthma Rep; 2024 Feb; 24(2):73-80. PubMed ID: 38217825
[TBL] [Abstract][Full Text] [Related]
26. New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.
Sehanobish E; Asad M; Jerschow E
Curr Opin Allergy Clin Immunol; 2022 Feb; 22(1):42-48. PubMed ID: 34739410
[TBL] [Abstract][Full Text] [Related]
27. Eosinophil production of prostaglandin D
Feng X; Ramsden MK; Negri J; Baker MG; Payne SC; Borish L; Steinke JW
J Allergy Clin Immunol; 2016 Oct; 138(4):1089-1097.e3. PubMed ID: 27423494
[TBL] [Abstract][Full Text] [Related]
28. Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis.
Stevens WW; Staudacher AG; Hulse KE; Poposki JA; Kato A; Carter RG; Suh LA; Norton JE; Huang JH; Peters AT; Grammer LC; Conley DB; Shintani-Smith S; Tan BK; Welch KC; Kern RC; Schleimer RP
J Allergy Clin Immunol; 2021 Aug; 148(2):439-449.e5. PubMed ID: 33819512
[TBL] [Abstract][Full Text] [Related]
29. A Review of Aspirin-exacerbated Respiratory Diseases and Immunological Efficacy of Aspirin Desensitization.
Esmaeilzadeh H; Zare M; Alyasin S; Nabavizadeh H; Mortazavi N; Kanannejad Z
Iran J Allergy Asthma Immunol; 2022 Oct; 21(5):512-523. PubMed ID: 36341560
[TBL] [Abstract][Full Text] [Related]
30. Cellular interactions in aspirin-exacerbated respiratory disease.
Badrani JH; Doherty TA
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):65-70. PubMed ID: 33306487
[TBL] [Abstract][Full Text] [Related]
31. The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
San Nicoló M; Högerle C; Gellrich D; Eder K; Pfrogner E; Gröger M
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):445-452. PubMed ID: 31655881
[TBL] [Abstract][Full Text] [Related]
32. Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).
Simon RA; Dazy KM; Waldram JD
Curr Allergy Asthma Rep; 2015 Mar; 15(3):508. PubMed ID: 25663486
[TBL] [Abstract][Full Text] [Related]
33. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease.
Scott WC; Cahill KN; Milne GL; Li P; Sheng Q; Huang LC; Dennis S; Snyder J; Bauer AM; Chandra RK; Chowdhury NI; Turner JH
J Allergy Clin Immunol; 2021 Apr; 147(4):1318-1328.e5. PubMed ID: 33189729
[TBL] [Abstract][Full Text] [Related]
34. IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Dwyer DF; Ordovas-Montanes J; Katz HR; Lewis E; Vukovic M; Lai J; Bankova LG; Bhattacharyya N; Shalek AK; Barrett NA; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2020 Jun; 145(6):1574-1584. PubMed ID: 32199912
[TBL] [Abstract][Full Text] [Related]
35. Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease.
Luskin K; Thakrar H; White A
Immunol Allergy Clin North Am; 2020 May; 40(2):329-343. PubMed ID: 32278455
[TBL] [Abstract][Full Text] [Related]
36. Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs.
Simon RA
Curr Allergy Asthma Rep; 2004 Jan; 4(1):17-24. PubMed ID: 14680616
[TBL] [Abstract][Full Text] [Related]
37. Update on Aspirin-Exacerbated Respiratory Disease.
Woessner KM
Curr Allergy Asthma Rep; 2017 Jan; 17(1):2. PubMed ID: 28097500
[TBL] [Abstract][Full Text] [Related]
38. Aspirin-exacerbated respiratory disease and current treatment modalities.
Sakalar EG; Muluk NB; Kar M; Cingi C
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1291-1300. PubMed ID: 27538737
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms by which dupilumab normalizes eicosanoid metabolism and restores aspirin-tolerance in AERD: A hypothesis.
Picado C; Mullol J; Roca-Ferrer J
J Allergy Clin Immunol; 2023 Feb; 151(2):310-313. PubMed ID: 36126795
[TBL] [Abstract][Full Text] [Related]
40. Cytokine and Lipid Mediator Regulation of Group 2 Innate Lymphoid Cells (ILC2s) in Human Allergic Airway Disease.
Cavagnero K; Doherty TA
J Cytokine Biol; 2017 Aug; 2(2):. PubMed ID: 28959799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
